CLINICAL TRIALS PROFILE FOR CARISOPRODOL
✉ Email this page to a colleague
All Clinical Trials for CARISOPRODOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00671502 ↗ | A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back | Completed | Meda Pharmaceuticals | Phase 3 | 2008-04-01 | The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo. |
| NCT00671879 ↗ | Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back | Completed | Meda Pharmaceuticals | Phase 3 | 2008-04-01 | The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo. |
| NCT01421433 ↗ | A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol | Unknown status | Pharmagenix Projetos em Medicina Farmacêutica Ltda. | Phase 3 | 2012-05-01 | Non inferiority, multicentric, double blind study whose the primary objective is to compare the effectiveness of two products in pain reduction. Primary endpoint: reduction in pain average at day 7 compared to day 1(baseline), using Analogue Visual Scale (AVS) for pain evaluation. Secondary endpoint: to evaluate the products safety at the gastrointestinal system. |
| NCT01421433 ↗ | A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol | Unknown status | Farmoquimica S.A. | Phase 3 | 2012-05-01 | Non inferiority, multicentric, double blind study whose the primary objective is to compare the effectiveness of two products in pain reduction. Primary endpoint: reduction in pain average at day 7 compared to day 1(baseline), using Analogue Visual Scale (AVS) for pain evaluation. Secondary endpoint: to evaluate the products safety at the gastrointestinal system. |
| NCT03508167 ↗ | Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. | Withdrawn | Ache Laboratorios Farmaceuticos S.A. | Phase 3 | 2020-01-01 | National clinical trial, phase III, monocentric, randomized, double-blind, controlled, parallel, study of superiority, in which two hundred and thirty four (234) participants of both sexes, aged equal or more than 18 years and equal or less than 54 years, will be randomly allocated in one of two treatment groups. The first group will use Dorilax® plus thermal band and the second group will use thermal band plus placebo. The results will show the efficacy and security of Dorilax® and compare the efficiency of Dorilax® and thermal band. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CARISOPRODOL
Condition Name
Clinical Trial Locations for CARISOPRODOL
Trials by Country
Clinical Trial Progress for CARISOPRODOL
Clinical Trial Phase
Clinical Trial Sponsors for CARISOPRODOL
Sponsor Name
